Peter Johnson

发表

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.

D. Dunlop, C. Fegan, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.